Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, provides an overview of the PROGRESS II trial, which was conducted for patients with hematologic malignancies.
Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses the results of a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia whose disease had progressed after treatment with either ibrutinib or idelalisib.
Koichi Takahashi, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study exploring a potential biomarker for patients likely to develop therapy-related leukemia.
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses phase III results of a study exploring rituximab as maintenance therapy after autologous stem cell transplantation in younger patients with mantle cell lymphoma.
Kathryn Kolibaba, MD, co-chair, Hematology Research Committee, US Oncology Research, discusses a study of entospletinib in the treatment of patients with mantle cell lymphoma.
Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the next steps to take with pelvic intensity-modulated radiation therapy for patients with gynecological cancers.
Anna C. Pavlick, DO, medical oncologist, NYU Langone School of Medicine, discusses ongoing clinical trials exploring treatment with immunotherapy in patients with basal cell carcinoma as well as squamous cell carcinoma.
Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses important factors for oncologists to consider when treating patients with colorectal cancer.
Jonas de Souza, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some of the upcoming next steps regarding immunotherapy in head and neck cancer.
Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses some of the challenges that oncologists may face when administering immunotherapy agents to patients with melanoma.
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses how the treatment landscape of mantle cell lymphoma is evolving.
Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).
Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the FDA approval of rucaparib for as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.
John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).
Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.
Stefani Spranger, PhD, postdoctoral fellow, Cancer Research Institute at The University of Chicago, discusses immune checkpoint blockade therapies that are currently being used to treat patients with melanoma.
Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.
Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses 2 exciting, ongoing phase III randomized trials in melanoma.
Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the use of immunotherapy in patients with head and neck cancer who have residual disease following treatment with chemotherapy and radiation.
Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.
Luciano Mutti, MD, professor in Cancer Research, University of Salford Manchester, discusses predicting clinical response to immunotherapy agents for patients with mesothelioma.
Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).
Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses risk categories that stratified patients in a study evaluating intensity-modulated radiation therapy and stereotactic body radiation therapy to determine outcomes in the reirradiation setting for recurrent head and neck cancer.
Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.
Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.
Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.
Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.
Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.
Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.
Ricardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.
